An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics
International Journal of Toxicology
Published online on January 22, 2026
Abstract
International Journal of Toxicology, Volume 45, Issue 2, Page 127-135, March/April 2026.
Oligonucleotide therapeutics (ONTs) are a growing class of nucleic acid–based therapies with the potential to treat a variety of diseases through several different mechanisms of action (MoA). The most prevalent MoA entails the inhibition of ...
Oligonucleotide therapeutics (ONTs) are a growing class of nucleic acid–based therapies with the potential to treat a variety of diseases through several different mechanisms of action (MoA). The most prevalent MoA entails the inhibition of ...